THE INCIDENCE, MORTALITY, AND SURVIVAL OF MALIGNANT PROSTATE CANCER IN THE UNITED STATES: A SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) 2000-2023 DATABASE ANALYSIS
Author(s)
Vlad Zah, PhD, Filip Stanicic, PhD (c), Dimitrije Grbic, PhD (c).
Health Economist, ZRx Outcomes Research, Inc., Mississauga, ON, Canada.
Health Economist, ZRx Outcomes Research, Inc., Mississauga, ON, Canada.
OBJECTIVES: Exploring the disease burden of prostate cancer (PC) in US using updated Surveillance, Epidemiology, and End Results (SEER) data released in April 2026.
METHODS: Data analysis from 21 cancer registries (2000-2023) was performed using SEER*Stat. Patients with PC were identified based on the primary site location. Only malignant cases were included. Study outcomes were incidence and mortality rates (crude, per 100,000 population) and survival (5-year rates). Annual percent change (APC), calculated using weighted least squares method, was used to investigate incidence and mortality trends.
RESULTS: Final sample had 2,297,306 PC patients, with 95.3% of them having adenocarcinoma. Patients were mostly elderly (61.4%), Non-Hispanic Whites (68.5%), residing in metropolitan counties (87.6%), and had annual household income (AHI) of $65,000-$90,000 (48.3%). PC incidence was 67.188 in the general US population and 136.017 in the US male population. The rate among elderly patients was 316.714, while 43.441 in patients aged 20-64 years. Non-Hispanic Whites and Blacks had similar incidence rates (84.594 and 84.574). PC was more common in non-metropolitan residents (78.694) and $120,000+ AHI patients (75.126). Incidence trend was stable between 2000-2023 (APC 0.086, p≥0.050). PC mortality was 25.219 in the general US population and 51.032 in the US male population. The rate was highest in Non-Hispanic Whites (33.411). Mortality was higher among non-metropolitan residents (34.389) and <$40,000 AHI patients (34.055). Mortality trends significantly increased from 2000 to 2023 (APC 6.899, p<0.050). 5-year survival rate for PC was high (84.1%). Across demographic subgroups, the lowest rates were observed for 90+ years old patients (14.4%), Non-Hispanic American Indians/Alaska Natives (79.6%), non-metropolitan residents (80.5%), and <$40,000 AHI (76.3%).
CONCLUSIONS: The study depicts a substantial increase in PC mortality in the US from 2000 to 2023, despite stable incidence trends. However, 5-year survival is high, suggesting successful management with innovative treatments in recent years.
METHODS: Data analysis from 21 cancer registries (2000-2023) was performed using SEER*Stat. Patients with PC were identified based on the primary site location. Only malignant cases were included. Study outcomes were incidence and mortality rates (crude, per 100,000 population) and survival (5-year rates). Annual percent change (APC), calculated using weighted least squares method, was used to investigate incidence and mortality trends.
RESULTS: Final sample had 2,297,306 PC patients, with 95.3% of them having adenocarcinoma. Patients were mostly elderly (61.4%), Non-Hispanic Whites (68.5%), residing in metropolitan counties (87.6%), and had annual household income (AHI) of $65,000-$90,000 (48.3%). PC incidence was 67.188 in the general US population and 136.017 in the US male population. The rate among elderly patients was 316.714, while 43.441 in patients aged 20-64 years. Non-Hispanic Whites and Blacks had similar incidence rates (84.594 and 84.574). PC was more common in non-metropolitan residents (78.694) and $120,000+ AHI patients (75.126). Incidence trend was stable between 2000-2023 (APC 0.086, p≥0.050). PC mortality was 25.219 in the general US population and 51.032 in the US male population. The rate was highest in Non-Hispanic Whites (33.411). Mortality was higher among non-metropolitan residents (34.389) and <$40,000 AHI patients (34.055). Mortality trends significantly increased from 2000 to 2023 (APC 6.899, p<0.050). 5-year survival rate for PC was high (84.1%). Across demographic subgroups, the lowest rates were observed for 90+ years old patients (14.4%), Non-Hispanic American Indians/Alaska Natives (79.6%), non-metropolitan residents (80.5%), and <$40,000 AHI (76.3%).
CONCLUSIONS: The study depicts a substantial increase in PC mortality in the US from 2000 to 2023, despite stable incidence trends. However, 5-year survival is high, suggesting successful management with innovative treatments in recent years.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EPH136
Topic
Clinical Outcomes, Epidemiology & Public Health, Real World Data & Information Systems
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology, Reproductive & Sexual Health